Diosmin

Chronic venous insufficiency is a common clinical vascular degenerative disease. Patients often present with symptoms such as lower limb swelling, pain, varicose veins and even ulcers, which seriously affect the quality of life. As a representative variety of flavonoid vascular protective agents, diosmin acts precisely on the pathological links of vascular diseases through three mechanisms of action: enhancing venous tone, reducing capillary permeability, and improving lymphatic return. In addition to venous diseases, it is also widely used for symptom relief of acute hemorrhoid attacks, covering multiple groups such as middle-aged and elderly chronic disease patients, people with sedentary or long-standing occupations, and patients with postoperative edema. It is one of the basic medications in the field of vascular disease treatment.

Diosmin is a mature variety with stable clinical demand, and its related preparations have long occupied the forefront of the vascular protective drug market. According to public data, the annual market size of diosmin at the terminal of domestic public medical institutions has exceeded 2 billion yuan, and the compound growth rate in the past three years has remained at around 5%. The demand growth is directly related to population aging and the rising prevalence of varicose veins. At present, the domestic preparation market is dominated by generic drugs. More than 30 enterprises have obtained approval for marketing of diosmin preparations, among which 17 enterprises have passed the consistency evaluation for their products. After being included in the local centralized procurement lists for many times, its clinical accessibility has been continuously improved.

The original research enterprise of diosmin is Servier in France, with the original brand name "Alvenor". Its core compound patent expired in 2001. The core dosage form is tablet, and the mainstream specification is 0.5g. The original research preparation has been included in the China Listed Drug Catalogue as a reference preparation, and is also included in the FDA Reference Preparation Catalogue. In terms of domestic API registration, as of now, more than 10 enterprises have obtained Class A status for their diosmin APIs through the CDE registration platform, which can be used for joint review with preparations. A number of generic preparations have been approved for marketing in China, covering multiple dosage forms including tablets. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO provides a full set of impurity reference standards for diosmin API. All products meet the compliance requirements of multiple regulatory systems such as the Chinese Pharmacopoeia and FDA. Most products are available in stock. For in-stock products, orders placed before 16:00 can be shipped on the same day, which can fully meet the needs of pharmaceutical enterprises in the whole process of R&D, quality research and production quality control.